TITLE

Potential Effects of Fluticasone Propionate on Bone Mineral Density in Patients With Asthma: A 2-Year Randomized, Double-Blind Placebo-Controlled Trial

AUTHOR(S)
Kemp, James P.; Osur, Scott; Shrewsbury, Stephen B.; Herje, Nancy E.; Duke, Susan P.; Harding, Stuart M.; Faulkner, Kennethf; Crim, Courtney C.
PUB. DATE
April 2004
SOURCE
Mayo Clinic Proceedings;Apr2004, Vol. 79 Issue 4, p458
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
• Objective: To evaluate the effects of treatment with fluticasone propionate vs placebo on bone, hypothalamicpituitary-adrenal (HPA) axis function, and the eyes in patients with asthma. • Patients and Methods: This randomized, double-blind, placebo-controlled study of 160 patients with asthma who had minimal previous exposure to corticosteroids was conducted from July 1994 through June 1997. Patients received fluticasone at 88 µg twice dally, fiuticasone at 440 µg twice daily, or placebo twice daily for 2 years. Bone mineral density (BMD) was evaluated every 6 months by lumbar spine, proximal femur, and total body scans. Measurements of HPA axis function and ophthalmic evaluations were conducted at similar intervals. • Results: Among the 3 groups, no significant differences were observed in BMD at week 104 (at any anatomical site). Mean percent change from baseline in the lumbar spine was less than 1% for all 3 groups. At all time points, HPA axis function was similar in the 88-µg fluticasone group compared with the placebo group. For mean change from baseline in corticotropin-stimulated peak cortisol (P=.003 and P=.02 at weeks 24 and 52, respectively) and area under the stimulated plasma cortisol vs time curve (P=.002 and P=.02 at weeks 24 and 52, respectively), statistically significant reductions from baseline were observed in the 440-µg fluticasone group compared with the placebo group. These reductions of 10% to 13% from baseline were not accompanied by other signs of systemic effect and did not persist with continued treatment (at weeks 76 and 104). No important ocular changes were observed. • Conclusion: Long-term treatment with 88 µg of fluticasone twice dally was comparable to placebo in all skeletal, ophthalmic, and HPA axis function assessments. Treatment with fluticasone at 440 µg twice daily resulted in no significant effects on BMD and a statistically significant but not clinically important temporary reduction in cortisol production.
ACCESSION #
12736170

 

Related Articles

  • Knowledge and perceptions of asthma in Zambia: a cross-sectional survey. Marsden, Emilia Jumbe; Somwe Wa Somwe; Chabala, Chishala; Soriano, Joan B.; Vallès, Cesar Picado; Anchochea, Julio; Jumbe Marsden, Emilia; Wa Somwe, Somwe; Somwe, Somwe Wa // BMC Pulmonary Medicine;2/12/2016, Vol. 16, p1 

    Background: Zambia is currently experiencing an epidemiological transition, from communicable to non-communicable diseases. The annual rate of physician-diagnosed asthma is estimated at 3 %. However, the general public's knowledge of asthma symptoms and signs, and their perception...

  • SECTION 15 RESPIRATORY DISORDERS.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, p228 

    The article offers information on several medications for respiratory disorders. The Arcapta Neohaler, a long-acting beta-2 agonist (LABA), is developed for the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). Asthmatic patients can be treated with...

  • SECTION 18 RESPIRATORY TRACT.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, p216 

    The article offers information on several drugs used to treat asthma and chronic obstructive pulmonary disease (COPD). These drugs include Asmanex Twisthaler from Schering AG, Azmacort from Kos Pharmaceuticals Inc. and Alupent Inhaler from Boehringer Ingelheim Pharmaceuticals Inc. An overview of...

  • Learning to Breathe. Lawrence, Jean // H&HN: Hospitals & Health Networks;Dec99, Vol. 73 Issue 12, p16 

    Focuses on the asthma management program in Yonkers, New York. Percentage of students that suffer from asthma; How the program started; Number of treatments that were given in 1997.

  • Advair blows off strong competition to remain first choice.  // PharmacoEconomics & Outcomes News;5/15/2010, Issue 603, p11 

    The article focuses on a report by Decision Resources, which indicated that Advair from GlaxoSmithKline remain the first choice of U.S. pulmonologists and primary care physicians (PCP) for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

  • Asthma and COPD. Allen, Stephen // Pulse;9/22/2010, Vol. 70 Issue 27, p30 

    The article discusses the long-term maintenance treatment to patients with chronic obstructive pulmonary diseases (COPD) and asthma.

  • A management strategy that controls lower airway eosinophilic inflammation and symptoms reduced exacerbations in asthma. Green, R. H.; Brightling, C. E.; McKenna, S.; Pavord, I. D. // Evidence Based Medicine;Jul2003, p113 

    The article presents a study that compares the effectiveness of standard care and management strategy in reducing lower airway eosinophilic symptoms and inflammation of asthma exacerbations of patients in Leicester, England. Researchers did a blinded randomized controlled trials of the 74...

  • Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD. Svedsater, Henrik; Dale, Peter; Garrill, Karl; Walker, Richard; Woepse, Mark W. // BMC Pulmonary Medicine;2013, Vol. 13 Issue 1, p1 

    Background Medications for respiratory disorders including asthma and chronic obstructive pulmonary disease (COPD) are typically delivered to the lung by means of a handheld inhaler. Patient preference for and ability to use the inhaler may influence their adherence to maintenance therapy, and...

  • Inhalers and patient education.  // American Family Physician;7/1/1994, Vol. 50 Issue 1, p186 

    Determines health care providers' knowledge and ability in demonstrating the use of metered-dose inhalers, spacers and breath-actuated dry powder inhalers for treatment of asthma and chronic obstructive pulmonary disease. Demonstration scores of respiratory therapists, nurses and physicians;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics